A novel therapeutic to ameliorate chronic pain and reduce opiate use

Ended Cooperative Agreement Awarded Last action

Award ID
UG3DA047680
Recipient
Awarding agency
Obligated
$5,634,909

Award facts

Assistance listing
93.279 Drug Use and Addiction Research Programs
Completion date
Originally
Funding agency
National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
Place of performance
Colorado, USA

Award details come from USAspending.gov.

Transactions

Action Obligated Date
Amendment $17,990
Amendment $17,990
Amendment -$17,990
Amendment -$17,990
Amendment -$17,990
Amendment $0
Amendment A novel therapeutic to ameliorate chronic pain and reduce opiate use - over 100 million adults in the U.S. Suffer from intermittent or constant chronic pain,… $0
Amendment -$3,270,473
Amendment $3,270,473
Amendment $3,270,473
Amendment $0
Original award $2,382,426
Show all 12

Quick answers

Who received award UG3DA047680?

UG3DA047680 was awarded to Lohocla Research Corp by National Institute on Drug Abuse (National Institutes of Health) on March 15, 2019.

How much is award UG3DA047680 worth?

$5,634,909 has been obligated on UG3DA047680.

Which agency awarded UG3DA047680?

National Institute on Drug Abuse (National Institutes of Health) awarded UG3DA047680, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award